The HRT-Prevents-Heart-Disease Doctrine — a 16,608-Woman Trial Halted for Causing the Heart Attacks

On 8 July 2002, the writing group of the Women’s Health Initiative announced that it had stopped the estrogen-plus-progestin arm of its trial roughly three years early, after a mean of 5.2 years, because the combined hormone regimen taken by 16,608 healthy postmenopausal women had increased coronary heart disease rather than preventing it — a hazard ratio of 1.29, alongside elevated stroke (1.41), breast cancer (1.26), and blood clots (roughly doubled). The promise and the reality had been inverted: for nearly two decades, conjugated equine estrogen had been prescribed to protect women’s hearts on the strength of observational data, and the first large randomized test of that promise in healthy women found the hearts were marginally worse off. The gap between the doctrine and the data would be counted in millions of prescriptions written for a benefit that did not exist.

The cardioprotection belief was not a fringe idea. It was mainstream preventive cardiology, taught in medical schools and embedded in clinical guidance, resting on some 40 to 50 observational studies — most prominently the Nurses’ Health Study, which reported current HRT users with coronary heart disease risk reduced by roughly 40 percent (relative risk near 0.61). Conjugated equine estrogen, sold by Wyeth as Premarin since 1942 and as the estrogen-progestin combination Prempro from 1995, exceeded two billion dollars in sales in 2001. The molecules were never recalled; they remain licensed today for menopausal symptoms. What collapsed in July 2002 was the theory attached to them — the claim that they prevented heart disease — displaced not by a scandal or a fraud but by the single most decisive instrument in clinical medicine: a large, randomized, placebo-controlled trial pointed directly at the question the observational data had only ever circled.

The reversal had been foreshadowed. In 1998, the HERS trial — 2,763 women who already had coronary disease, randomized to estrogen-plus-progestin or placebo — had found no overall benefit for secondary prevention, and a 50 percent excess of cardiac events in the first year. The field absorbed HERS as a special case (sick women, late timing) and held to the primary-prevention promise. WHI tested that promise in healthy women, and it failed too. The market answered within months: combined-therapy prescriptions fell by roughly two-thirds within a year, and in 2003 the US Food and Drug Administration imposed a class-wide boxed warning.

This dossier files “Overturned” entry TH-006 as the archetype of a different failure than fraud. No one falsified data. A generation of physicians inferred causation from correlation in self-selected, healthier-than-average hormone users, and only a randomized trial could break the spell — long after the prescription pads had done their work.

Female Hysteria — 2,400 Years of the ‘Wandering Womb,’ Deleted From the DSM in 1980

Hysteria entered Western medicine through the Hippocratic Corpus of the 5th and 4th centuries BC, which attributed a roster of female complaints — convulsions, suffocation, paralysis, mood disturbance — to a uterus that wandered the body in search of moisture, and the gap between that promise of explanation and its evidentiary basis never closed across the twenty-four centuries the diagnosis survived. The mechanism was anatomically impossible; Galen had said as much in the 2nd century AD, noting the womb could not “move from one place to another like a wandering animal.” Yet the label outlived its own physiology. What persisted was not the wandering-womb anatomy but the diagnostic habit it licensed: a single, elastic category onto which a clinician could map almost any unexplained symptom in a woman, and, by the 19th century, blame on her reproductive organs, her nerves, or her sex itself.

The diagnosis was never retracted by an experiment; it was dissolved by reclassification. By the late 1800s “hysteria” had become one of the most frequently assigned disorders in European and American medicine, a major form of neurotic illness diagnosed predominantly in women and treated with regimens ranging from marriage and pregnancy to the “rest cure,” pelvic manipulation, and, in extreme cases, surgical removal of the ovaries. Jean-Martin Charcot relocated it from the uterus to the nervous system at the Salpêtrière in the 1870s and 1880s; Sigmund Freud and Josef Breuer relocated it again, in their 1895 Studies on Hysteria, to repressed psychological trauma. Each move stripped away a layer of the original etiology without retiring the word.

The formal revocation came on a date psychiatry can name. When the American Psychiatric Association published the third edition of its Diagnostic and Statistical Manual in 1980, “hysterical neurosis” was deleted as a unified entity and its fragments redistributed into discrete, criteria-based diagnoses — conversion disorder, somatization disorder (the streamlined heir to Briquet’s syndrome), the dissociative disorders, and histrionic personality disorder. The wandering womb retains no medical standing whatsoever, and the gendered super-category that succeeded it was judged too vague, too sexed, and too entangled in bad science to survive contact with operational criteria.

This dossier files “Overturned” entry TH-009 as the archetype of a theory revoked not by a single trial but by an institution editing its own manual: a diagnosis that endured because it explained nothing and therefore could be made to explain anything, and that fell only when psychiatry agreed to require that a category say something specific.